Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Buske

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Blood Advances|May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphomaAnastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Blood|January 10, 2009
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCGJan Braess, Karsten Spiekermann, Peter Staib, et al.
Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
Hemasphere|September 5, 2024
Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upKai Hübel, Mark Bower, Igor Aurer, et al.
Blood|January 19, 2013
Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemiaEva Diffner, Dominik Beck, Emma Gudgin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.
Annals of Hematology|July 12, 2011
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)Friederike Schneider, Eva Hoster, Stephanie Schneider, et al.
Haematologica|December 9, 2017
Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemiaEdith Schneider, Anna Staffas, Linda Röhner, et al.
The Lancet. Haematology|November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trialMichinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Blood Advances|May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphomaAnastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Blood|January 10, 2009
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCGJan Braess, Karsten Spiekermann, Peter Staib, et al.
Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
Hemasphere|September 5, 2024
Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upKai Hübel, Mark Bower, Igor Aurer, et al.
Blood|January 19, 2013
Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemiaEva Diffner, Dominik Beck, Emma Gudgin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.
Annals of Hematology|July 12, 2011
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)Friederike Schneider, Eva Hoster, Stephanie Schneider, et al.
Haematologica|December 9, 2017
Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemiaEdith Schneider, Anna Staffas, Linda Röhner, et al.
The Lancet. Haematology|November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trialMichinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Pageof 15